Lalitha Sundararaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lalitha Sundararaman has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Basavana Goudra
Department of Anesthesiology, Sidney Kimmel Medical College, Jefferson Health, Philadelphia, PA, USA
5 shared publications - Michael Stuart Green
Department of Anesthesiology and Perioperative Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
3 shared publications - Prarthna Chandar
Sidney Kimmel Medical College
3 shared publications - Divakara Gouda
Department of Medicine, Inspira Health Network, 155 Bridgeton Pike Suite C, Mullica Hill, NJ 08062, USA
1 shared publication - Kelly Elizabeth Hathorn
Harvard Medical School
1 shared publication - R. Anil Kumar
Assistant Professor, Karnataka Institute of Endocrinology and Research Bangalore, Karnataka, India
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7709
Reply to Fernández et al. Comment on “Goudra et al. Anesthesia for Bronchoscopy—An Update. J. Clin. Med. 2024, 13, 6471”
Thank you for reading our review and providing valuable feedback
- 30 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7709
Open AccessReply to Fernández et al. Comment on “Goudra et al. Anesthesia for Bronchoscopy—An Update. J. Clin. Med. 2024, 13, 6471”
Thank you for reading our review and providing valuable feedback
- Open Access
- 14 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1978
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), the first of which, exenatide, was approved by the FDA in 2005. Two other major classes of drugs have also entered the market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins and approved in 2006, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors, with the first approval occurring in 2013. These drugs have revolutionized the treatment of diabetes. Additionally, on the horizon, the once-weekly basal insulin analog insulin icodec and the once-weekly combination of insulin icodec and semaglutide are expected to be available in the future. Beyond glycemic control, GLP1RAs have exhibited benefits in conditions associated with diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, as well as in neurodegenerative diseases such as Alzheimer’s disease. Additionally, emerging research suggests potential roles in certain types of cancer, infertility, and associative learning. Major cardiovascular events seem to be lower in patients on GLP1RAs. While some evidence is robust, other findings remain tenuous. It is important that clinicians are familiar with current research in order to provide optimal evidence-based care to patients. In the not-too-distant future, there may be a case to prescribe these drugs for benefits outside diabetes.
- 14 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1978
Open AccessGlucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), the first of which, exenatide, was approved by the FDA in 2005. Two other major classes of drugs have also entered the market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins and approved in 2006, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors, with the first approval occurring in 2013. These drugs have revolutionized the treatment of diabetes. Additionally, on the horizon, the once-weekly basal insulin analog insulin icodec and the once-weekly combination of insulin icodec and semaglutide are expected to be available in the future. Beyond glycemic control, GLP1RAs have exhibited benefits in conditions associated with diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, as well as in neurodegenerative diseases such as Alzheimer’s disease. Additionally, emerging research suggests potential roles in certain types of cancer, infertility, and associative learning. Major cardiovascular events seem to be lower in patients on GLP1RAs. While some evidence is robust, other findings remain tenuous. It is important that clinicians are familiar with current research in order to provide optimal evidence-based care to patients. In the not-too-distant future, there may be a case to prescribe these drugs for benefits outside diabetes.
- Open Access
- 29 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6471
Anesthesia for Bronchoscopy—An Update
The field of interventional pulmonology has grown immensely and is increasingly recognized as a subspecialty. The new procedures introduced in the last decade pose unique challenges, and anesthesiologists need to readapt to their specific demands. In this review, we extensively discuss the pathophysiology, technical aspects, preprocedural preparation, anesthetic management, and postprocedural challenges of many new procedures such as navigational bronchoscopy, endobronchial valve deployment, and bronchial thermoplasty. Majority of these procedures are performed under general anesthesia with an endotracheal tube. Total intravenous anesthesia with rocuronium as a muscle relaxant seems to be the standard US practice. The easy availability and proven safety and efficacy of sugammadex as a reversal agent of rocuronium has decreased the need for high-dose remifentanil as an agent to avoid muscle relaxants. Additional research is available with regard to the utility of nebulized lidocaine and is discussed. Finally, two newer drugs administered for conscious sedation (typically without the need of an anesthesiologist) are likely to gain popularity in the future. Remimazolam is a new short-acting benzodiazepine with a relatively faster offset of clinical effects. Dexmedetomidine, a selective adrenergic agonist, is increasingly employed in bronchoscopy as a sedative during bronchoscopic procedures.
- 29 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6471
Open AccessAnesthesia for Bronchoscopy—An Update
The field of interventional pulmonology has grown immensely and is increasingly recognized as a subspecialty. The new procedures introduced in the last decade pose unique challenges, and anesthesiologists need to readapt to their specific demands. In this review, we extensively discuss the pathophysiology, technical aspects, preprocedural preparation, anesthetic management, and postprocedural challenges of many new procedures such as navigational bronchoscopy, endobronchial valve deployment, and bronchial thermoplasty. Majority of these procedures are performed under general anesthesia with an endotracheal tube. Total intravenous anesthesia with rocuronium as a muscle relaxant seems to be the standard US practice. The easy availability and proven safety and efficacy of sugammadex as a reversal agent of rocuronium has decreased the need for high-dose remifentanil as an agent to avoid muscle relaxants. Additional research is available with regard to the utility of nebulized lidocaine and is discussed. Finally, two newer drugs administered for conscious sedation (typically without the need of an anesthesiologist) are likely to gain popularity in the future. Remimazolam is a new short-acting benzodiazepine with a relatively faster offset of clinical effects. Dexmedetomidine, a selective adrenergic agonist, is increasingly employed in bronchoscopy as a sedative during bronchoscopic procedures.
- Open Access
- 20 September 2024
- Published by MDPI AG in Preprints.org
Anesthesia for Bronchoscopy-An Update
The field of interventional pulmonology has grown immensely and is increasingly recognized as a subspecialty. The new procedures introduced in the last decade pose unique challenges and the anesthesia providers need to readapt to their specific demands. In this review, we have discussed extensively the pathophysiology, technical aspects, preprocedural preparation, anesthetic management and postprocedural challenges of many new procedures such as navigational bronchoscopy, endobronchial valve deployment and bronchial thermoplasty. Majority of these procedures are performed under general anesthesia with an endotracheal tube. Total intravenous anesthesia with rocuronium as a muscle relaxant seems to the standard US practice. Easy availability and proven safety and efficacy of sugammadex as a reversal agent of rocuronium has decreased the need for high dose remifentanil as an agent to avoid muscle relaxants. Additional research is available with regards to the utility of nebulized lidocaine and is discussed. Finally, two newer drugs administered for conscious sedation (typically without the need of an anesthesia provider) are likely to gain popularity in the future. Remimazolam is a new short acting benzodiazepine with relatively faster offset of clinical effect. Dexmedetomidine, a selective adrenergic agonist, is increasingly employed in bronchoscopy as a sedative during bronchoscopic procedures.
- 20 September 2024
- Published by MDPI AG in Preprints.org
Open AccessAnesthesia for Bronchoscopy-An Update
The field of interventional pulmonology has grown immensely and is increasingly recognized as a subspecialty. The new procedures introduced in the last decade pose unique challenges and the anesthesia providers need to readapt to their specific demands. In this review, we have discussed extensively the pathophysiology, technical aspects, preprocedural preparation, anesthetic management and postprocedural challenges of many new procedures such as navigational bronchoscopy, endobronchial valve deployment and bronchial thermoplasty. Majority of these procedures are performed under general anesthesia with an endotracheal tube. Total intravenous anesthesia with rocuronium as a muscle relaxant seems to the standard US practice. Easy availability and proven safety and efficacy of sugammadex as a reversal agent of rocuronium has decreased the need for high dose remifentanil as an agent to avoid muscle relaxants. Additional research is available with regards to the utility of nebulized lidocaine and is discussed. Finally, two newer drugs administered for conscious sedation (typically without the need of an anesthesia provider) are likely to gain popularity in the future. Remimazolam is a new short acting benzodiazepine with relatively faster offset of clinical effect. Dexmedetomidine, a selective adrenergic agonist, is increasingly employed in bronchoscopy as a sedative during bronchoscopic procedures.
- Open Access
- 8 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4635
Sedation for GI Endoscopy in the Morbidly Obese: Challenges and Possible Solutions
With the increasing prevalence of obesity and morbid obesity, this subgroup’s contribution to patients presenting for elective procedures requiring sedation is significant. Gastrointestinal (GI) procedures clearly form the largest group of such procedures. These procedures may be intended to treat obesity such as the insertion of an intragastric balloon or one or more unrelated procedures such as a screening colonoscopy and (or) diagnostic/therapeutic endoscopy. Regardless of the procedure, these patients pose significant challenges in terms of choice of sedatives, dosing, airway management, ventilation, and oxygenation. An understanding of dissimilarity in the handling of different groups of medications used by an anesthesia provider and alterations in airway anatomy is critical for providing safe sedation. Administration of sedative medications and conduct of anesthesia requires dose modifications and airway adjuncts. In this review, we discuss the above issues in detail, with a particular focus on GI endoscopy.
- 8 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4635
Open AccessSedation for GI Endoscopy in the Morbidly Obese: Challenges and Possible Solutions
With the increasing prevalence of obesity and morbid obesity, this subgroup’s contribution to patients presenting for elective procedures requiring sedation is significant. Gastrointestinal (GI) procedures clearly form the largest group of such procedures. These procedures may be intended to treat obesity such as the insertion of an intragastric balloon or one or more unrelated procedures such as a screening colonoscopy and (or) diagnostic/therapeutic endoscopy. Regardless of the procedure, these patients pose significant challenges in terms of choice of sedatives, dosing, airway management, ventilation, and oxygenation. An understanding of dissimilarity in the handling of different groups of medications used by an anesthesia provider and alterations in airway anatomy is critical for providing safe sedation. Administration of sedative medications and conduct of anesthesia requires dose modifications and airway adjuncts. In this review, we discuss the above issues in detail, with a particular focus on GI endoscopy.
- 1 January 2024
- Published by Springer Nature
- p. 299-304
Anesthetic Considerations of Bariatric Endoscopy
- 1 January 2024
- Published by Springer Nature
- p. 299-304
Anesthetic Considerations of Bariatric Endoscopy